Press

Welcome to the APEX Press room. Please check back often for updates and news, and don’t hesitate to reach out to info@apexlabs.com with questions or requests.

Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial

06.12.25

Apex Labs files IND with FDA for microdose psilocybin study

06.10.24

Apex Labs Files for US Patent Protecting Psychedelic Drug Delivery System

03.07.24

Apex Labs Granted Dealer’s Licence by Health Canada

02.15.24

Apex Labs Applauds Senate Subcommittee’s Endorsement for Expanded Access to Psychedelic-Assisted Therapy for Veterans

11.17.23

Cision

Canadian Veteran Dosed with First Cycle of APEX-90 Macrodose Psilocybin in Apex Labs’ Early Access Program.

11.02.23

Canadian Veteran Receives Approval for APEX’s Psilocybin Therapy Through Health Canada’s Special Access Program

10.05.23

Cision

Apex Labs announces the appointment of Chief Medical Officer & Chief Commercial Officer

08.18.23

Cision

Apex Labs Receives Approval for US-Based Secondary GMP Psilocybin Supplier by Health Canada

06.09.23